RnRMarketResearch.com adds “Hepatic (Liver) Metastasis – Pipeline Review, H1 2015” to its store. This report provides an overview of the Hepatic (Liver) Metastasis’s therapeutic pipeline.

Dallas, TX -- (SBWire) -- 06/08/2015 --The report "Hepatic (Liver) Metastasis – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Hepatic (Liver) Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic (Liver) Metastasis and special features on late-stage and discontinued projects.

Complete report on Hepatic (Liver) Metastasis with 24 market data tables and 15 figures, spread across 61 pages is available at http://www.rnrmarketresearch.com/hepatic-liver-metastasis-pipeline-review-h1-2015-market-report.html .

Companies discussed in this Hepatic (Liver) Metastasis – Pipeline Review, H1 2015 report include BioCancell Therapeutics, Inc., CytRx Corporation, Digna Biotech, S.L., Gradalis Inc., Incuron, LLC, Novartis AG, Phosplatin Therapeutics LLC, Targetome.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are Antibodies to Inhibit FRMD4A for Oncology, BC-821, cancer vaccine, Cell Therapy to Target CEA for Oncology, Cyt-HiPoA, DB-02901, mepacrine, Monoclonal Antibody Conjugated to Activate p53 for Hepatic Metastasis, pasireotide, PT-112, Recombinant Protein to Antagonize IGF-1R for Liver Metastasis and Breast Cancer, TGM-002, TGM-003.

Featured News & Press Releases cover by this report includes: Apr 16, 2014: Cleveland BioLabs Announces the Successful Completion of a Phase 1 Study of CBL0102.

Order a purchase copy of this report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=388735

(This is a premium report priced at US$2000 for a single user License.)

List of Tables
Number of Products under Development for Hepatic (Liver) Metastasis, H1 2015 8
Number of Products under Development for Hepatic (Liver) Metastasis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Hepatic (Liver) Metastasis - Pipeline by BioCancell Therapeutics, Inc., H1 2015 16
Hepatic (Liver) Metastasis - Pipeline by CytRx Corporation, H1 2015 17
Hepatic (Liver) Metastasis - Pipeline by Digna Biotech, S.L., H1 2015 18
Hepatic (Liver) Metastasis - Pipeline by Gradalis Inc., H1 2015 19
Hepatic (Liver) Metastasis - Pipeline by Incuron, LLC, H1 2015 20
Hepatic (Liver) Metastasis - Pipeline by Novartis AG, H1 2015 21
Hepatic (Liver) Metastasis - Pipeline by Phosplatin Therapeutics LLC, H1 2015 22
Hepatic (Liver) Metastasis - Pipeline by Targetome, H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Hepatic (Liver) Metastasis Therapeutics - Recent Pipeline Updates, H1 2015 50
Hepatic (Liver) Metastasis - Dormant Projects, H1 2015 56
Hepatic (Liver) Metastasis - Discontinued Products, H1 2015 57

List of Figures
Number of Products under Development for Hepatic (Liver) Metastasis, H1 2015 8
Number of Products under Development for Hepatic (Liver) Metastasis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Top 10 Targets, H1 2015 25
Number of Products by Stage and Top 10 Targets, H1 2015 26
Number of Products by Top 10 Mechanism of Actions, H1 2015 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Top 10 Routes of Administration, H1 2015 29
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30
Number of Products by Top 10 Molecule Types, H1 2015 31
Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Explore more reports on Therapeutics at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.